DOJ Antitrust Division Announces Deferred Prosecution Agreements with Two Pharmaceutical Companies Containing “Extraordinary” Divestiture Remedy
Article
United States: Pharmaceutical Antitrust 2024
Alert
Where Things Stand on Drug Pricing at the Halfway Point of 2023
Insight
Tech continues to dominate
Last year was a volatile 12 months for the tech sector, with a steep sell-off in growth stocks and a drop in IPOs—but, although the sector was down, it was by no means out
Insight
PMB performs as pharma groups repurpose their portfolios
After a year of historic profits in 2021 following the mass roll-out of COVID-19 vaccines and related treatments, big pharma companies armed with cash for deals have been shifting their attention
Alert
Five Drug Pricing Issues to Watch in 2023
Alert
Strong Medicine: Using Investment Treaties to Mitigate Foreign Regulatory Risk in the Life Sciences
Article
United States: Pharmaceutical Antitrust 2023
Alert
2022 Drug Pricing Update: States Continue Legislative Push Even As Congress Passes Long Sought Changes
Alert
Federal Legislators and FTC Keep PBMs Center Stage in Drug Pricing Debate
Alert
Drug Pricing Issues to Watch in 2022
Article
Lexology GTDT: EU Antitrust Developments in the Pharmaceutical Sector
Article
United States: Pharmaceutical Antitrust 2022
Alert
HHS Report Reiterates Biden Administration Support for Wide-Ranging Action to Address Drug Prices
Alert
States Remain the Drivers of New Drug Pricing Legislation As Washington Weighs In
Alert
House Republicans Introduce Bill to Renew 2015 Trade Promotion Authority Law and Establish New Negotiating Objectives for Pharmaceuticals
Alert
What Does President Biden’s July 9, 2021 Executive Order on Competition Mean for the Pharma Industry?
Insight
Global PE posts record buyout value in Q2 thanks to TMT, pharma
Increasing cooperation between global PE players is pushing up price tags
Insight
What’s next for drug pricing in the US?
New challenges may lie ahead for the pharmaceutical industry
Alert
Federal Lawmakers Turn Their Sights to Drug Pricing, Introducing a Package of Bills Seeking Changes to Antitrust and Patent Law
Insight
US antitrust spotlight on the pharmaceutical industry
Companies seeking mergers can expect scrutiny and litigation
Alert
President Biden Signs Legislation Boosting Generic and Biosimilar Drugs
Alert
Elimination of Medicaid Rebate Cap in the Latest COVID-19 Relief Package—The First Legislative Action on Drug Pricing Under the Biden Administration
Insight
Healthcare M&A activity heats up in H2
M&A value in the healthcare sector (incorporating pharma, medical and biotech) stayed relatively robust in 2020, even without the kind of blockbuster deals the sector had become accustomed to seeing in recent years
Alert
Supreme Court Green Lights Arkansas Law Regulating PBM Pricing Practices
Alert
Trump Administration’s Eleventh-Hour Drug Pricing Regulations Face an Uncertain Path Forward
Article
United States: Pharmaceutical Antitrust 2021
Alert
President Trump's Most Favored Nation Policy for Medicare Drug Costs Unlikely to Bring Near Term Changes
Alert
Uncertainty on Drug Pricing Remains Following Trump Administration Executive Orders
Article
Why A Surge In Drug Pricing Litigation Is Unlikely
Insight
Accelerating change: From smart city to smart society
The COVID-19 pandemic has revealed some of the shortcomings of major cities in times of crisis. As the world searches for ways to make urban areas more resilient, smart city initiatives offer some of the answers.
Article
Analysis: Lamictal highlights increased class action scrutiny in pharma cases
Alert
Growing Web of State Drug-Pricing Legislation Increases Challenges for Pharmaceutical Manufacturers and Other Industry Participants
Alert
Court of Appeal broadly upholds the CAT's judgment in Phenytoin and clarifies "excessive pricing" test
Authorities can't stick their head in the sand – they have to consider different types of evidence
Alert
Impact of the CARES Act on the Medical Device Industry
Alert
Impact of the CARES Act on the Pharmaceutical and Medical Devices Industries
Alert
FTC and FDA Announce Plans to Combat Anticompetitive Practices in the "Biologic Marketplace"
Alert
New State Laws Target Key Issues in the Ongoing Drug Pricing Debate
Alert
California's New Reverse Payment Law Departs from Supreme Court Standard in FTC v. Actavis
